Clinical trials Below are current clinical trials.501 studies in Oncology (Medical) (open studies only). Filter this list of studies by location, status and more. Efficacy and Safety of REC-2282 in Participants with Progressive NF2 Mutated Meningiomas (POPLAR-NF2) Rochester, Minn. The purpose of this study is to investigate the effectiveness and safety of REC-2282 in patients with progressive NF2 mutated meningiomas who have either NF2 disease-related meningioma or sporadic meningiomas that have NF2 mutations. A Registry Study for the Long-Term Outcomes of Radiation Therapy Scottsdale/Phoenix, Ariz. The purpose of this long term registry study is to collect and analyze information from patients being treated with various forms of radiation therapy to improve the treatment of future patients. Grief Among Older Adult Family Caregivers Jacksonville, Fla. The purpose of this study is to evaluate the trajectory of loss and grief over 12 months, the risk factors associated with high levels of pre-loss grief, and the preliminary effectiveness of ART for treatment of high levels of pre-loss grief among family caregivers (FCG) of persons nearing the end of life. A Study to Collect Medical and Personal Histories, Blood and/or Tumor Tissue Samples from Patients Who are Long-term Survivors of Lung Cancer Rochester, Minn. The purpose of this study is to collect medical and personal histories, blood and/or tumor tissue samples from patients who are long-term survivors of lung cancer. This study will help us to develop better ways to provide care and advice, develop better treatments to minimize long-term side effects, and improve the quality of life and outcome of lung cancer patients. This study will also help us to learn whether certain genes (inherited factors from your parents) increase the risk of developing or dying of lung cancer. Melanoma In-transit Tissue Bank and Molecular Analysis for Personalized Therapies Rochester, Minn. The purpose of this study is to establish a tissue bank to collect patient tissue for genomic analysis, allowing identification of genomic signatures that predict response and failure to the individual therapy. Once this is complete treatment will be directed based on the genomic signature of patients individual tumor. A Study of Intratumoral Injection of Dendritic Cells after High-Dose Conformal External Beam Radiotherapy in Patients with Unresectable Liver Cancer Rochester, Minn. Group 1: The primary purpose of this study is to evaluate the safety and tolerability of an autologous dendritic cells (DC) vaccine delivered by intra-tumoral injection in patients with primary liver cancer treated with high-dose conformal external beam radiotherapy (EBRT). Group 2: The primary purpose of this study is to estimate the progression-free survival rate at 2 years post-registration to see if treatment is efficacious compared to historical data Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors Rochester, Minn. The purpose of this study is to evaluate the safety and effectiveness of using Exablate Model 4000 Type-2.0/2.1 in adults with Glioblastoma brain tumors to increase temporarily the permeability of the blood brain barrier, allowing increased passage of circulating free DNA (cfDNA) for sampling and analysis. Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma Scottsdale/Phoenix, Ariz. Primary Goal: To determine the toxicity of in-house, manufactured MUC1-activated T cells in patients with relapsed/refractory MUC1-expressing multiple myeloma. The rationale for using MUC1-stimulated T-cells to treat multiple myeloma is twofold. The first is that T-cell therapies have been shown to be active in myeloma, making it an attractive disease model for the proposed study. The other is that we are expanding and using naturally occurring myeloma-fighting T-cells which may offer benefits, particularly with respect to longevity, as compared to the methods currently being employed using CAR-T and bispecific antibodies. This is highly significant as one of the main limitations of current T-cell therapies is their limited duration of action. Long range, having demonstrated the utility of MUC1-stimulated T-cells in myeloma, we will expand the use to common MUC1+ solid tumors (breast, colon, lung), as well as expand the pool of antigens that may be targeted. Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or CCUS Rochester, Minn., Mankato, Minn., La Crosse, Wis., Eau Claire, Wis. The purpose of this study is to examine how well ascorbic acid and combination chemotherapy work in treating patients with lymphoma that has come back or does not respond to therapy. Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may work better at treating lymphoma. In the Clonal Cytopenia of Undetermined Significance (CCUS) Cohort D, we want to find out if ascorbic acid will improve blood counts so fewer transfusions are required and there is a less likely chance the patient will develop myelodysplastic syndrome (MDS) or other related myeloid malignancies. Real-time Disease Monitoring of Metastatic Breast Cancer to Optimize Treatment Scottsdale/Phoenix, Ariz. The purpose of this study is to identify subtype-specific signatures for breast cancer using genomic positioning of plasma DNA fragments, and to validate changes in ctDNA levels as a biomarker for treatment monitoring in patients with metastatic breast cancer. Pagination Clinical studies PrevPrevious Page Go to page 3434 Go to page 3535 Go to page 3636 Go to page 3737 Go to page 3838 NextNext Page Request an appointment Expertise & rankingsResearch May 09, 2023 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, have been recognized among the top Cancer hospitals in the nation for 2024-2025 by U.S. News & World Report. Learn more about this top honor Oncology (Medical)DepartmenthomeSectionsOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20180179 Medical Departments & Centers Oncology (Medical)